Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
or

Acadia Pharmaceutica (ACAD)

Acadia Pharmaceutica (ACAD)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
14.73 -0.10 (-0.67%) 04/25/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 14.73 unch (unch) 16:20 ET
Quote Overview for Fri, Apr 25th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
14.47
Day High
14.83
Open 14.78
Previous Close 14.83 14.83
Volume 957,500 957,500
Avg Vol 1,702,285 1,702,285
Stochastic %K 51.24% 51.24%
Weighted Alpha -16.07 -16.07
5-Day Change unch (unch) unch (unch)
52-Week Range 13.40 - 20.68 13.40 - 20.68
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,565,215
  • Shares Outstanding, K 166,789
  • Annual Sales, $ 957,800 K
  • Annual Income, $ 226,450 K
  • EBIT $ 84 M
  • EBITDA $ 91 M
  • 60-Month Beta 0.54
  • Price/Sales 2.57
  • Price/Cash Flow 20.90
  • Price/Book 3.34

Options Overview Details

View History
  • Implied Volatility 68.58% ( +5.10%)
  • Historical Volatility 42.89%
  • IV Percentile 82%
  • IV Rank 45.29%
  • IV High 127.33% on 04/16/25
  • IV Low 19.95% on 09/19/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1,120
  • Volume Avg (30-Day) 1,155
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 26,447
  • Open Int (30-Day) 25,858

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 0.05
  • Number of Estimates 9
  • High Estimate 0.28
  • Low Estimate -0.42
  • Prior Year 0.10
  • Growth Rate Est. (year over year) -50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.40 +9.93%
on 04/09/25
Period Open: 17.11
17.31 -14.90%
on 03/27/25
-2.38 (-13.91%)
since 03/25/25
3-Month
13.40 +9.93%
on 04/09/25
Period Open: 18.67
20.68 -28.77%
on 02/21/25
-3.94 (-21.10%)
since 01/24/25
52-Week
13.40 +9.93%
on 04/09/25
Period Open: 16.31
20.68 -28.77%
on 02/21/25
-1.58 (-9.69%)
since 04/25/24

Most Recent Stories

More News
Soleno Therapeutics: Navigating the Path to Profitability with Vykat XR

Summary First-Mover Advantage: Soleno has the market to itself until competition intensifies. High Sales Potential: Projected sales of $876 million by 2030 are highly attractive. Commercial Challenges:...

ACAD : 14.73 (-0.67%)
AARD : 7.93 (-3.53%)
SLNO : 73.26 (-1.31%)
Analysts Love These 2 Growth Stocks That Have Over 200% Upside Potential

Wall Street expects both of these biotech stocks to soar over 200% in the next 12 months.

AKBA : 2.38 (+4.39%)
STOK : 9.76 (-1.21%)
ACAD : 14.73 (-0.67%)
BIIB : 118.84 (-0.56%)
Will Auvelity & Other Drugs Aid AXSM's Growth Amid Stiff Competition?

Axsome Therapeutics’ AXSM Auvelity (AXS-05) was launched in the United States in 2022 for the treatment of major depressive disorder (MDD), making it the first approved drug in the company’s portfolio.Auvelity...

JAZZ : 110.80 (+1.67%)
ACAD : 14.73 (-0.67%)
AXSM : 106.27 (+0.82%)
Acadia: Q4 Earnings Snapshot

Acadia: Q4 Earnings Snapshot

ACAD : 14.73 (-0.67%)
2 ‘Strong Buy’ Stocks Under $10 Set to Surge as Much as 331%

These biotech companies are poised for significant long-term growth. However, there are risks.

$SPX : 5,525.21 (+0.74%)
STOK : 9.76 (-1.21%)
ACAD : 14.73 (-0.67%)
PHAT : 4.11 (-0.24%)
BIIB : 118.84 (-0.56%)
Is the Options Market Predicting a Spike in ACADIA Pharmaceuticals (ACAD) Stock?

Investors in Acadia Pharmaceuticals Inc. ACAD need to pay close attention to the stock based on moves in the options market lately. That is because the Mar 21, 2025 $12 Put had some of the highest implied...

ACAD : 14.73 (-0.67%)
ACAD Seeks EU Nod for Rett Syndrome Drug, Outlines 2025 Pipeline Goals (Revised)

Acadia Pharmaceuticals ACAD announced that it has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) seeking approval for trofinetide to treat Rett syndrome in...

CTMX : 0.7100 (-7.29%)
VYGR : 3.47 (-1.70%)
CSTL : 20.63 (-1.43%)
ACAD : 14.73 (-0.67%)
ACAD Seeks EU Nod for Rett Syndrome Drug, Outlines 2025 Pipeline Goals

Acadia Pharmaceuticals ACAD announced that it has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) seeking approval for trofinetide to treat Rett syndrome in...

CTMX : 0.7100 (-7.29%)
VYGR : 3.47 (-1.70%)
CSTL : 20.63 (-1.43%)
ACAD : 14.73 (-0.67%)
Stocks Rally on Strength in Megacap Tech and Chip Makers

The S&P 500 Index ($SPX ) (SPY ) Friday closed up +1.26%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.80%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.67%. March E-mini S&P...

GOOGL : 161.96 (+1.68%)
TAP : 56.80 (-2.66%)
BF.B : 33.96 (-1.88%)
$IUXX : 19,432.56 (+1.14%)
ZNM25 : 111-165s (+0.27%)
MSFT : 391.85 (+1.17%)
TSLA : 284.95 (+9.80%)
ESM25 : 5,549.75s (+0.70%)
PHM : 101.88 (-0.94%)
QCOM : 148.56 (+0.92%)
JBL : 146.92 (+0.54%)
AMD : 96.64 (+2.30%)
Stocks Climb Ahead of Dec ISM Manufacturing Report

The S&P 500 Index ($SPX ) (SPY ) today is up +0.51%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.27%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.80%. March E-mini S&P futures (ESH25...

GOOGL : 161.96 (+1.68%)
TAP : 56.80 (-2.66%)
BF : 59.80 (-0.25%)
$IUXX : 19,432.56 (+1.14%)
ZNM25 : 111-165s (+0.27%)
TSLA : 284.95 (+9.80%)
RRR : 42.60 (+1.84%)
ESM25 : 5,549.75s (+0.70%)
PHM : 101.88 (-0.94%)
CHWY : 36.80 (+2.14%)
X : 42.68 (+0.99%)
STZ : 185.35 (-1.15%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing innovative medicines to address the unmet medical needs in central nervous system (CNS) disorders. The company's sole marketed drug Nuplazid (pimavanserin) is the first and the only FDA-approved treatment for hallucinations...

See More

Key Turning Points

3rd Resistance Point 15.24
2nd Resistance Point 15.04
1st Resistance Point 14.88
Last Price 14.73
1st Support Level 14.52
2nd Support Level 14.32
3rd Support Level 14.16

See More

52-Week High 20.68
Fibonacci 61.8% 17.90
Fibonacci 50% 17.04
Fibonacci 38.2% 16.18
Last Price 14.73
52-Week Low 13.40

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective